Schrödinger and ChemAxon Ltd. Extend Partnership

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK and BUDAPEST, Hungary, July 9, 2013 /PRNewswire/ --

Schrödinger, Inc. and ChemAxon jointly announced today that they have extended their partnership agreement for another five years. In the expanded agreement, ChemAxon will provide the JChem chemistry engine as well as Marvin sketching and rendering functionality to Schrödinger's enterprise informatics platform, Seurat. "We're very excited to continue our partnership," said Schrödinger's President, Dr. Ramy Farid, "and we look forward to working more closely with ChemAxon and exploiting their powerful cheminformatics tools."

A data integration and discovery collaboration platform, Seurat provides decision and project support as well as advanced data exploration, and can consume backend data or replace legacy tools like Accord™, ISIS™, Isentris™, or internally developed customer tools that have reached end of life. Seurat can be installed locally, or hosted on either the British Telecom (BT) or Amazon Web Services (AWS) cloud. The expanded agreement will also allow Schrödinger to plug in additional ChemAxon software as required.

"The extension of our agreement underlines ChemAxon's position and reputation as the leading provider of chemistry search and management expertise, and complements Schrödinger's leading modelling and computational chemistry expertise," commented Alex Drijver, CEO of ChemAxon. "Its long-term nature demonstrates that collaboration between partners with complementary technologies is a sustainable business model in our sector, and in fact can offer a better solution to customers and a more efficient development environment for partners; we see this trend increasing as more partners place their chemistry requirements with ChemAxon."

ChemAxon's JChem chemistry engine, able to be deployed universally and scale to cover big data requirements, is the industry's leading chemical structure storage and search toolkit. Also included in the provision is the JKlustor functionality for high performance structure library analysis as well as the renowned Marvin editor & viewer which lets users ask chemical questions and see structures as answers.

About Schrödinger

Schrödinger makes significant investments in R&D, which has led to major advances in the field of computational chemistry; it has achieved breakthroughs in quantum chemistry, molecular modeling, force fields, molecular dynamics, protein structure determination, scoring, and virtual screening. The company's full product offerings range from general molecular modeling programs to a comprehensive suite of drug design software. Besides the company's industry-leading drug discovery solutions, Schrödinger is actively developing state-of-the art simulation tools for materials research as well as enterprise software that can be deployed throughout an entire research organization. Schrödinger's methods development and applications papers have thousands of citations and are often among the most-cited scientific publications. Schrödinger's science is continually validated internally and by its users worldwide. Founded in 1990, Schrödinger has operations in the United States as well as in Europe, India, and Japan.

About ChemAxon

ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across North America.

Help employers find you! Check out all the jobs and post your resume.

Back to news